[Prospective study on nylestriol replacement therapy in postmenopausal women].

A prospective study was carried out on 283 postmenopausal women to evaluate the nylestriol effect from Jan. 1989 to July 1992. Menopausal year ranged from 1-26 years. The women were divided randomly into three groups. Group A: the nylestriol were given 2 mg/2 weeks, 136 cases, group B: 1 mg/2 weeks, 97 cases, group C: placebo/2 weeks, 50 cases. The results showed: (1) High-density-lipoprotein cholesterol increased and low-density-lipoprotein cholesterol decreased in both group A and B (P < 0.05), but not in the placebo group (P < 0.05). (2) Both the group A and B had significant lessening of serum alkaline phosphatase, ratios of calcium to creatinine and hydroxyproline to creatinine (P < 0.05). (3) The mineral content of distal and proximal forearm bone remained unchanged in both group A and B (P > 0.05), but decreased significantly in placebos (P < 0.01). (4) The Kupperman index score in both group A and B decreased significantly in 3 month (P < 0.05). (5) Curettage were performed 205 times in group A and B. Histological diagnosis revealed neither carcinoma nor atypical endometrial hyperplasia. (6) No breast cancer was found. In conclusion, nylestriol is a convenient and acceptable drug which was beneficial for relieving climacteric syndrome, preventing osteoporosis and improving lipoprotein lipid pattern.